Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Enhancing MRD detection through an ultrasensitive ctDNA test: Insights from real-world clinical data.

Real-world performance of NeXT Personal Dx in more than 5,000 people across 15 cancer types. Median limit of detection was 1.90 parts per million, and 45.3% of tests were ctDNA-positive. This is an analytical performance abstract, not a treatment trial. No public poster file is linked from the abstract page.

American Association for Cancer Research Annual Meeting 2026